Related Experiment Video
Updated: Mar 6, 2026

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
Public (un)willingness to trade-off benefits and harms in decisions about cancer screening: A discrete choice
Rebecca A Dennison1, Stuart Wright2, Georgios Lyratzopoulos3
1Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
Abstract:
ObjectivesTo quantify the harms participants are willing to accept for varying benefits from cancer screening following provision of information.MethodsWe conducted an online discrete choice experiment with two samples of the UK public. Attributes were number of cancer diagnoses and deaths prevented (benefits) and overdiagnoses, false positives and false negatives (harms) for a population who are/are not screened for an unspecified cancer over their lifetimes. After selecting the best-fitting conditional logistic regression model for each sample, we used latent class analysis to investigate preference heterogeneity and calculated the probability that each class/group would take up screening with different benefit and harm levels.ResultsIn total, 1018 participants completed the discrete choice experiment. Cancer deaths prevented was the most important attribute, followed by the number of false positively/negatively detected cancers; cancers prevented and overdiagnosed were deemed relatively unimportant. Three latent classes were identified. The largest class (approximately two-thirds) chiefly opted for screening, focusing on deaths prevented; this group would strongly prefer screening participation even with harms only (probability 76%-92%). Approximately a quarter of each sample traded off benefits and harms; this group would likely take up screening with outcomes like those of colorectal screening (68%-87%).ConclusionsA minority of the public express preferences for screening that are influenced by trading-off potential benefits/harms, but most have strong preferences for cancer screening, focusing on the associated reduction of cancer deaths. The findings emphasise public health responsibility in appraising or generating evidence on benefits and harms to support decisions about the introduction or modification of screening programmes.
Related Concept Videos
Nursing Ethical Principles II
Consider the following scenario, which illustrates how these principles are applied in the care of Mr. John, a fifty-year-old teacher diagnosed with metastatic liver cancer.
Initially, Mr. John's...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Cancer Prevention
Some...
Cancer Survival Analysis
Hazard Ratio
For example, in a clinical trial...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

